Juvenile idiopathic arthritis-associated uveitis

Current Opinion in Ophthalmology

Volumn 21, Issue 6, 2010, Pages 468-472

  Qian, Ying ^a,b   Acharya, Nisha R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

immunomodulatory therapy; immunosuppression; juvenile idiopathic arthritis; uveitis

Indexed keywords

CORTICOSTEROID; FLUOCINOLONE ACETONIDE; IMMUNOMODULATING AGENT;

CATARACT EXTRACTION; CILIARY DISK; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EYE SYNECHIA; FOLLOW UP; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INTRAOCULAR PRESSURE; JUVENILE IDIOPATHIC ARTHRITIS ASSOCIATED UVEITIS; JUVENILE RHEUMATOID ARTHRITIS; MORBIDITY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX DIFFERENCE; UVEITIS; VISUAL ACUITY; VITRECTOMY;

ARTHRITIS, JUVENILE RHEUMATOID; EYE DISEASES; HUMANS; IMMUNOMODULATION; UVEITIS;

EID: 78049255827     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32833eab83     Document Type: Review

References (45)

1. Ravelli A, Felici E, Magni-Manzoni S, et al. Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum 2005; 52:826-832.
2. Thorne JE, Woreta F, Kedhar SR, et al. Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol 2007; 143:840-846.
3. Macaubas C, Nguyen K, Milojevic D, et al. Oligoarticularand polyarticular JIA: epidemiology and pathogenesis. Nat Rev Rheumatol 2009; 5:616-626.
4. Heiligenhaus A, Niewerth M, Ganser G, et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford) 2007; 46:1015-1019.
5. Asproudis I, Felekis T, Tsanou E, et al. Juvenile idiopathic arthritis-associated uveitis: data from a region in western Greece. Clin Ophthalmol 2010; 4:343-347.
6. Woreta F, Thorne JE, Jabs DA, et al. Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol 2007; 143:647-655.
7. Saurenmann RK, Levin AV, Feldman BM, et al. Risk factors for development of uveitis differ between girls and boys with juvenile idiopathic arthritis. Arthritis Rheum 2010; 62:1824-1828.
8. Ayuso VK, Ten Cate HA, van der Does P, et al. Male gender as a risk factor for complications in uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol 2010; 149:994-999.
9. Ayuso VK, Ten Cate HA, van der Does P, et al. Male gender and poor visual outcome in uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol 2010; 149:987-993.
10. Thorne JE, Woreta FA, Dunn JP, et al. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology 2010; 117:1436-1441.
11. Ilowite NT. Update on biologics in juvenile idiopathic arthritis. Curr Opin Rheumatol 2008; 20:613-618.
12. Hayward K, Wallace CA. Recent developments in antirheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther 2009; 11:216.
13. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359:810-820.
14. Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372:383-391.
15. Ruperto N, Lovell DJ, Quartier P, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010; 62:1792-1802.
16. Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007; 56:3096-3106.
17. Ruperto N, Lovell DJ, Cuttica R, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010; 69:718-722.
18. Tappeiner C, Roesel M, Heinz C, et al. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye (Lond) 2009; 23:1192-1198.
19. Simonini G, Cantarini L, Bresci C, et al. Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmun Rev 2010; 9:674-683.
20. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005; 53:18-23.
21. Angeles-Han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: a case report. J Rheumatol 2008; 35:1897-1898.
22. Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe antitumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken) 2010; 62:821-825.
23. Sen HN, Levy-Clarke G, Faia LJ, et al. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol 2009; 148:696.e1-703.e1.
24. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295:2275-2285.
25. Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 2009; 339:b2480.
26. Jancevski M, Foster CS. Cataracts and uveitis. Curr Opin Ophthalmol 2010; 21:10-14.
27. Van Gelder RN, Leveque TK. Cataract surgery in the setting of uveitis. Curr Opin Ophthalmol 2009; 20:42-45.
28. Holland GN. Intraocular lens implantation in patients with juvenile rheumatoid arthritis-associated uveitis: an unresolved management issue. Am J Ophthalmol 1996; 122:255-257.
29. Probst LE, Holland EJ. Intraocular lens implantation in patients with juvenile rheumatoid arthritis. Am J Ophthalmol 1996; 122:161-170.
30. BenEzra D, Cohen E. Cataract surgery in children with chronic uveitis. Ophthalmology 2000; 107:1255-1260.
31. Quinones K, Cervantes-Castaneda RA, Hynes AY, et al. Outcomes of cataract surgery in children with chronic uveitis. J Cataract Refract Surg 2009; 35:725-731.
32. Adan A, Gris O, Pelegrin L, et al. Explantation of intraocular lenses in children with juvenile idiopathic arthritis-associated uveitis. J Cataract Refract Surg 2009; 35:603-605.
33. Verbraeken H. Pars plana lensectomy in cases of cataract with juvenile chronic uveitis. Graefes Arch Clin Exp Ophthalmol 1996; 234:618-622.
34. Androudi S, Ahmed M, Fiore T, et al. Combined pars plana vitrectomy and phacoemulsification to restore visual acuity in patients with chronic uveitis. J Cataract Refract Surg 2005; 31:472-478.
35. Soheilian M, Mirdehghan SA, Peyman GA. Sutureless combined 25-gauge vitrectomy, phacoemulsification, and posterior chamber intraocular lens implantation for management of uveitic cataract associated with posterior segment disease. Retina 2008; 28:941-946.
36. Acevedo S, Quinones K, Rao V, et al. Cataract surgery in children with juvenile idiopathic arthritis associated uveitis. Int Ophthalmol Clin 2008; 48:1-7.
37. Sijssens KM, Los LI, Rothova A, et al. Long-term ocular complications in aphakic versus pseudophakic eyes of children with juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol 2010 Jun 16. [Epub ahead of print]
38. Jaffe GJ, Martin D, Callanan D, et al. Fluocinoloneacetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006; 113:1020-1027.
39. Callanan DG, Jaffe GJ, Martin DF, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008; 126:1191-1201.
40. Kempen JH, Altaweel MM, Holbrook JT, et al. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol 2010; 149:550.e10-561.e10.
41. Verbraeken H. Therapeutic pars plana vitrectomy for chronic uveitis: a retrospective study of the long-term results. Graefes Arch Clin Exp Ophthalmol 1996; 234:288-293.
42. Giuliari GP, Chang PY, Thakuria P, et al. Pars plana vitrectomy in the management of paediatric uveitis: the Massachusetts eye research and surgery Institution experience. Eye (Lond) 2010; 24:7-13.
43. Skarin A, Elborgh R, Edlund E, et al. Long-term follow-up of patients with uveitis associated with juvenile idiopathic arthritis: a cohort study. Ocul Immunol Inflamm 2009; 17:104-108.
44. Camuglia JE, Whitford CL, Hall AJ. Juvenile idiopathic arthritis associated uveitis in adults: a case series. Ocul Immunol Inflamm 2009; 17:330-334.
45. Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010; 303:1266-1273.